Literature DB >> 23822890

Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.

Mi Kyoung Kim1, Seok Ju Seong, Taejong Song, Mi-La Kim, Bo Sung Yoon, Hye Sun Jun, Gun Ho Lee, Yoon Hee Lee.   

Abstract

OBJECTIVE: To compare the diagnostic accuracy of dilatation & curettage (D&C) vs. endometrial aspiration biopsy in follow-up evaluation of patients treated with high-dose oral progestin plus levonorgestrel intrauterine system (LNG-IUS) for early-stage endometrial cancer (EC).
METHOD: A prospective observational study was conducted with 11 patients with FIGO grade 1 or 2, clinical stage IA endometrioid adenocarcinoma. Patients were aged up to 40 years wishing to preserve fertility treated with high-dose oral progestin plus LNG-IUS. Treatment response assessment was done at three month intervals. Endometrial tissues were obtained via endometrial aspiration biopsy with LNG-IUS in place and D&C after removal of LNG-IUS. We identified 28 cases; the histologic results were compared. Kappa statistics were used to assess the agreement of two methods.
RESULTS: Diagnostic concordance between examinations was assessed for 9 out of 28 cases examined (32.1%). These consisted of three cases with both examination results of normal, 3 cases with endometrioid adenocarcinoma, 1 case with complex endometrial hyperplasia, 2 cases with material insufficient for diagnosis. Endometrioid adenocarcinoma on D&C was diagnosed in 9 out of 28 cases, but from endometrial aspiration biopsy, only 3 of these 9 cases were diagnosed with endometrioid adenocarcinoma, giving the diagnostic concordance at 33% (kappa value=0.27). From endometrial aspiration biopsy, 17 out of 28 cases (60.7%) had material insufficiency for diagnosis.
CONCLUSION: In patients treated with high-dose oral progestin plus LNG-IUS for early-stage EC, endometrial aspiration biopsy with LNG-IUS in place may be not reliable as a follow-up evaluation method.
© 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dilatation & curettage; Endometrial biopsy; Endometrial cancer; LNG-IUS; Progesterone

Mesh:

Substances:

Year:  2013        PMID: 23822890     DOI: 10.1016/j.ygyno.2013.06.035

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management.

Authors:  Sinead H McEvoy; Stephanie Nougaret; Nadeem R Abu-Rustum; Hebert Alberto Vargas; Elizabeth A Sadowski; Christine O Menias; Fuki Shitano; Shinya Fujii; Ramon E Sosa; Joanna G Escalon; Evis Sala; Yulia Lakhman
Journal:  Abdom Radiol (NY)       Date:  2017-10

Review 2.  Fertility sparing surgery in gynecologic cancer.

Authors:  P Rema; Iqbal Ahmed
Journal:  J Obstet Gynaecol India       Date:  2014-06-03

Review 3.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Authors:  Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Oncologist       Date:  2015-02-11

4.  LNG-IUS treatment of non-atypical endometrial hyperplasia: Can Pipelle endometrial sampling be an accurate method of follow-up evaluation?

Authors:  Mi Kyoung Kim; Seok Ju Seong
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

Review 5.  Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia.

Authors:  Qing Zhang; Gonghua Qi; Margaux J Kanis; Ruifen Dong; Baoxia Cui; Xingsheng Yang; Beihua Kong
Journal:  Oncotarget       Date:  2017-05-03

6.  Fertility-sparing treatment in early endometrial cancer: current state and future strategies.

Authors:  Andreas Obermair; Eva Baxter; Donal J Brennan; Jessica N McAlpine; Jennifer J Muellerer; Frédéric Amant; Mignon D J M van Gent; Robert L Coleman; Shannon N Westin; Melinda S Yates; Camilla Krakstad; Monika Janda
Journal:  Obstet Gynecol Sci       Date:  2020-07-08

7.  Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.

Authors:  Mi Kyoung Kim; Seok Ju Seong; Soon Beom Kang; Duk Soo Bae; Jae Weon Kim; Joo Hyun Nam; Myong Cheol Lim; Taek Sang Lee; Sunghoon Kim; Jiheum Paek
Journal:  J Gynecol Oncol       Date:  2019-01-07       Impact factor: 4.401

8.  Fertility-sparing treatment in women with endometrial cancer.

Authors:  Seyeon Won; Mi Kyoung Kim; Seok Ju Seong
Journal:  Clin Exp Reprod Med       Date:  2020-11-10

9.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

Authors:  Nicoletta Colombo; Carien Creutzberg; Frederic Amant; Tjalling Bosse; Antonio González-Martín; Jonathan Ledermann; Christian Marth; Remi Nout; Denis Querleu; Mansoor Raza Mirza; Cristiana Sessa
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

10.  Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.

Authors:  Da Hee Kim; Seok Ju Seong; Mi Kyoung Kim; Hyo Sook Bae; Mi La Kim; Bo Seong Yun; Yong Wook Jung; Jeong Yun Shim
Journal:  J Gynecol Oncol       Date:  2016-08-02       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.